JP2024520861A - 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 - Google Patents

遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 Download PDF

Info

Publication number
JP2024520861A
JP2024520861A JP2023577141A JP2023577141A JP2024520861A JP 2024520861 A JP2024520861 A JP 2024520861A JP 2023577141 A JP2023577141 A JP 2023577141A JP 2023577141 A JP2023577141 A JP 2023577141A JP 2024520861 A JP2024520861 A JP 2024520861A
Authority
JP
Japan
Prior art keywords
seq
compound
peptide
isovaleric acid
palm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520861A5 (https=
Inventor
クマール グプタ，スニール
ワイ リウ，デイビッド
バチュラル モディ，ニシット
ホレス ヴァロン、フランク
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2024520861A publication Critical patent/JP2024520861A/ja
Publication of JP2024520861A5 publication Critical patent/JP2024520861A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2023577141A 2021-06-14 2022-06-14 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 Pending JP2024520861A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163210453P 2021-06-14 2021-06-14
US63/210,453 2021-06-14
US202163252001P 2021-10-04 2021-10-04
US63/252,001 2021-10-04
US202263349841P 2022-06-07 2022-06-07
US63/349,841 2022-06-07
PCT/US2022/033378 WO2022266060A1 (en) 2021-06-14 2022-06-14 Hepcidin mimetics for treatment of hereditary hemochromatosis

Publications (2)

Publication Number Publication Date
JP2024520861A true JP2024520861A (ja) 2024-05-24
JP2024520861A5 JP2024520861A5 (https=) 2025-06-23

Family

ID=84527344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577141A Pending JP2024520861A (ja) 2021-06-14 2022-06-14 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体

Country Status (11)

Country Link
US (1) US20240293511A1 (https=)
EP (2) EP4355763A4 (https=)
JP (1) JP2024520861A (https=)
KR (1) KR20240021833A (https=)
AU (1) AU2022293672A1 (https=)
BR (1) BR112023026381A2 (https=)
CA (1) CA3220871A1 (https=)
IL (1) IL309166A (https=)
MX (1) MX2023015021A (https=)
TW (1) TW202317604A (https=)
WO (1) WO2022266060A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
WO2025207760A1 (en) * 2024-03-27 2025-10-02 Protagonist Therapeutics, Inc. Formulations of a hepcidin peptide analogue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
WO2015200916A2 (en) * 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
EP3240799B1 (en) * 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
PH12022550510A1 (en) * 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
IL309166A (en) 2024-02-01
EP4737477A2 (en) 2026-05-06
US20240293511A1 (en) 2024-09-05
EP4355763A1 (en) 2024-04-24
KR20240021833A (ko) 2024-02-19
AU2022293672A9 (en) 2024-01-11
AU2022293672A1 (en) 2023-12-14
TW202317604A (zh) 2023-05-01
BR112023026381A2 (pt) 2024-03-05
WO2022266060A1 (en) 2022-12-22
CA3220871A1 (en) 2022-12-22
EP4355763A4 (en) 2025-07-30
MX2023015021A (es) 2024-01-26

Similar Documents

Publication Publication Date Title
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
US12269856B2 (en) Hepcidin analogues and uses thereof
JP7831841B2 (ja) コンジュゲートされたヘプシジン模倣物
JP2026048851A (ja) コンジュゲートされたヘプシジン模倣物
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
WO2022212698A1 (en) Conjugated hepcidin mimetics
US20250360187A1 (en) Hepcidin mimetics for treatment of sickle cell disease
TW585873B (en) Antagonistic analogs of GH-RH inhibiting IGF-I and -II
WO2024011188A1 (en) Combination therapy for treatment of iron overload diseases
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
EP3433259B1 (en) Conjugates of tacrolimus, their compositions, and their uses
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
WO2025196129A1 (en) Calcitonin gene-related peptide analogues
HK1220112B (en) Hepcidin analogues and uses therof

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613